Allergan plc (AGN)
| Market Cap | 63.66B |
| Revenue (ttm) | 16.10B |
| Net Income (ttm) | -2.49B |
| Shares Out | 328.28M |
| EPS (ttm) | -7.57 |
| PE Ratio | n/a |
| Forward PE | 11.89 |
| Dividend | $2.96 |
| Dividend Yield | 1.53% |
| Trading Day | May 8, 2020 |
| Last Price | $193.02 |
| Previous Close | $193.02 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 191.64 - 193.38 |
| Day's Volume | 0 |
| 52-Week Range | 114.27 - 202.22 |
News
LOS ANGELES--(BUSINESS WIRE)---- $AGN #AGN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc.
LOS ANGELES--(BUSINESS WIRE)---- $AGN #AGN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc.
The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products
New York Governor Andrew Cuomo said on Tuesday the State Department of Financial Services had filed charges against Teva Pharmaceuticals and Allergan Plc over their role in the opioid crisis.
DUBLIN, Aug. 14, 2020 /PRNewswire/ -- The "Global Breast Implant Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.
John Paulson (Trades, Portfolio)’s Paulson & Co. sold shares of the following stocks during the first quarter of 2020.
Abbvie CEO on Allergan acquisition, Covid-19's effect on demand and more
Abbvie CEO Richard Gonzalez joins "Squawk on the Street" to discuss the company's acquisition of Allergan, why the coronavirus pandemic has led to a demand curve, the effectiveness of migraine...
AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Is AbbVie stock a buy now?
Allergan PLC AGN, +0.01% said late Friday that AbbVie Inc. ABBV, -0.30% has closed its acquisition of the company.
With this final regulatory sign-off, the deal between these two pharmaceutical giants should close very soon.
Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.
The deal for AbbVie Inc. ABBV, +4.28% to buy Allergan Plc. AGN, +2.16% has cleared an antitrust hurdle, the companies said late Tuesday.
Final Trades: JPM, GDX, AAPL & AGN
The Fast Money traders offer up their final trades of the week.
On Allergan's (AGN) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Don't let the pandemic distract your attention from a monster acquisition - and a chance to own AGN stock before the deal's finalized. The post Buy Allergan Stock as Big Pharma’s Biggest Deal ...
Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The coronavirus has completely changed the narrative on AbbVie’s buyout of AGN. Allergan stock holders banking on it should reconsider.
And two of the three offer nice dividends, too.
Given recovering fundamentals, investors should take advantage of the beaten-down prices. For them, we have highlighted four solid ETF & stock picks each from the industries that are currently...
The coronavirus outbreak has made shares of top drugmakers more attractive than they've been in a quite a while.
AbbVie Inc. ABBV, -1.68% and Allergan PLC AGN, +4.34% announced Tuesday that they signed a consent decree with the U.S.
Allergan (AGN) reported earnings 30 days ago. What's next for the stock?
AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
It's the first time this type of gene-editing treatment has been tested on a human.
AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients
The pharmaceutical giant stands accused of making false and misleading product comparisons.
The groups are worried about reduced competition if the merger goes through.
A group of unions and consumer groups wrote to U.S. antitrust enforcers on Tuesday to oppose a proposed remedy that could lead to U.S.
Allergan + Cash Becomes More Compelling - February 12 Update
It's all about the lips with the soon-to-be-acquired company's latest advertising push.
Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Allergan (AGN) earnings for the pharmaceutical company's fourth quarter of 2019 have AGN stock up Monday after beating estimates.
The drugmaker delivered solid top- and bottom-line improvement as it awaited the closing of its acquisition by AbbVie.
The maker of Botox appears to be on an upswing just ahead of its megamerger with AbbVie.
Allergan plc (NYSE: AGN) reported quarterly earnings of $5.22 per share on Monday, beating the analyst consensus estimate of $4.57 by 14.22%.
Allergan (AGN) delivered earnings and revenue surprises of 13.23% and 6.26%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares of Allergan PLC AGN, +2.16% rose 1% in premarket trading Monday, after the drug maker reported a fourth-quarter adjusted profit and revenue that beat expectations.
Allergan earnings beat Q4 estimates. Shares rose modestly before the open.
Jim Cramer previews the week ahead of earnings reports from Allergan, Lyft, Nvidia and more companies
CNBC's Jim Cramer gives a preview of what he's looking for in corporate earnings reports in the coming week.
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q4 as loss of exclusivity of several products hurts sales.
Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.
This is already a huge week for earnings, as nearly half of the Dow Jones industrial average is reporting, and roughly 150 companies in the S&P 500 as well.
U.S. drugmaker AbbVie's $63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled company is shedding to placate regulators.
About AGN
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also o... [Read more...]
| Industry Drug Manufacturers—General | IPO Date Feb 17, 1993 |
| Stock Exchange NYSE | Ticker Symbol AGN |
Financial Performance
In 2019, Allergan's revenue was $16.09 billion, an increase of 1.91% compared to the previous year's $15.79 billion. Losses were -$5.27 billion, 3.43% more than in 2018.